Ultomiris (Ravulizumab), is a monoclonal antibody that specifically targets terminal
complement products and is proposed for the treatment of COVID-19 induced microvasculature
injury and endothelial damage leading to thrombotic microangiopathy (TMA) causing acute
kidney injury (AKI). Ravulizumab is to be used for participants with a confirmed diagnosis of
COVID-19 who clinically or diagnostically present with deteriorating renal function.
Ravulizumab causes immediate and sustained inhibition of the terminal complement cascade. The
use of ravulizumab could ameliorate COVID-19 induced kidney injury due to TMA, shorten
hospital stay, and improve the overall survival.